Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy has been described to markedly improve patient survival. However, reports describing the antitumor therapeutic efficacy and safety of ICIs in patients with autoantibodies are scarce. METHODS: This study examined the efficacy and feasibility of IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouri, Atsuto, Kaira, Kyoichi, Yamaguchi, Ou, Hashimoto, Kosuke, Miura, Yu, Shiono, Ayako, Shinomiya, Shun, Akagami, Tomoe, Imai, Hisao, Kobayashi, Kunihiko, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005657/
https://www.ncbi.nlm.nih.gov/pubmed/33791204
http://dx.doi.org/10.3389/fonc.2021.610952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005657/
https://www.ncbi.nlm.nih.gov/pubmed/33791204
http://dx.doi.org/10.3389/fonc.2021.610952

Ejemplares similares